Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor meetings to be conducted. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith is the details of Analyst/ Institutional Investor meeting to be conducted. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor meeting to be conducted. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor/ Broker meeting to be conducted. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor meetings to be conducted. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith are the details of Analyst/ Institutional Investor meetings to be conducted. Two Indian drugmakers to sell first biosimilar version of Cetuximab
Alkem, Lupin price biosimilar at sub-10,000 for a 100 mg vial Alkem launches biosimilar of Merck's Cetuximab to treat head and neck cancer
Alkem's Cetuxa has been researched and manufactured indigenously by Enzene Biosciences Limited, the biological arm of Alkem Laboratories Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith is the details of Analyst/ Institutional Investor meeting to be conducted.
Neutral Alkem Laboratories; target of Rs 3470: Motilal Oswal
Motilal Oswal recommended Neutral rating on Alkem Laboratories with a target price of Rs 3470 in its research report dated May 20, 2023.